These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8537683)

  • 21. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemophilia and nonprogressing human immunodeficiency virus type 1 infection.
    Vicenzi E; Bagnarelli P; Santagostino E; Ghezzi S; Alfano M; Sinnone MS; Fabio G; Turchetto L; Moretti G; Lazzarin A; Mantovani A; Mannucci PM; Clementi M; Gringeri A; Poli G
    Blood; 1997 Jan; 89(1):191-200. PubMed ID: 8978292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH; Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS
    J Infect Dis; 1996 Feb; 173(2):340-8. PubMed ID: 8568294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.
    Beaumont T; Broersen S; van Nuenen A; Huisman HG; de Roda Husman AM; Heeney JL; Schuitemaker H
    J Virol; 2000 Sep; 74(17):7699-707. PubMed ID: 10933675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of viral burden and phenotype of HIV-1 isolates from lymph nodes and blood.
    Tamalet C; Lafeuillade A; Yahi N; Vignoli C; Tourres C; Pellegrino P; de Micco P
    AIDS; 1994 Aug; 8(8):1083-8. PubMed ID: 7986403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparable biological and molecular determinants in HIV type 1-infected long-term nonprogressors and recently infected individuals.
    Balotta C; Bagnarelli P; Riva C; Valenza A; Antinori S; Colombo MC; Sampaolesi R; Violin M; de Pasquale MP; Moroni M; Clementi M; Galli M
    AIDS Res Hum Retroviruses; 1997 Mar; 13(4):337-41. PubMed ID: 9071433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).
    Zhou J; Montefiori DC
    Virology; 1996 Dec; 226(1):13-21. PubMed ID: 8941318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.
    Lathey JL; Tsou J; Brinker K; Hsia K; Meyer WA; Spector SA
    J Infect Dis; 1999 Aug; 180(2):344-50. PubMed ID: 10395848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conserved neutralizing epitopes of HIV type 1 CRF01_AE against primary isolates in long-term nonprogressors.
    Sreepian A; Srisurapanon S; Horthongkham N; Tunsupasawasdikul S; Kaoriangudom S; Khusmith S; Sutthent R
    AIDS Res Hum Retroviruses; 2004 May; 20(5):531-42. PubMed ID: 15186528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.
    Tsang ML; Evans LA; McQueen P; Hurren L; Byrne C; Penny R; Tindall B; Cooper DA
    J Infect Dis; 1994 Nov; 170(5):1141-7. PubMed ID: 7963706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.
    Hioe CE; Xu S; Chigurupati P; Burda S; Williams C; Gorny MK; Zolla-Pazner S
    Int Immunol; 1997 Sep; 9(9):1281-90. PubMed ID: 9310831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients.
    Moja P; Tranchat C; Tchou I; Pozzetto B; Lucht F; Desgranges C; Genin C
    J Infect Dis; 2000 May; 181(5):1607-13. PubMed ID: 10823760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.
    Willey S; Aasa-Chapman MM; O'Farrell S; Pellegrino P; Williams I; Weiss RA; Neil SJ
    Retrovirology; 2011 Mar; 8():16. PubMed ID: 21401915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Herpesvirus saimiri-immortalized human lymphocytes: novel hosts for analyzing HIV type 1 in vitro neutralization.
    Vella C; Zheng NN; Easterbrook P; Daniels RS
    AIDS Res Hum Retroviruses; 2002 Sep; 18(13):933-46. PubMed ID: 12230936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies.
    Tremblay M; Numazaki K; Li XG; Gornitsky M; Hiscott J; Wainberg MA
    J Immunol; 1990 Nov; 145(9):2896-901. PubMed ID: 1698866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection.
    Tóth FD; Szabó B; Ujhelyi E; Pálóczi K; Horváth A; Füst G; Kiss J; Bánhegyi D; Hollán SR
    AIDS; 1991 Mar; 5(3):263-8. PubMed ID: 1676275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.
    Arendrup M; Nielsen C; Hansen JE; Pedersen C; Mathiesen L; Nielsen JO
    J Acquir Immune Defic Syndr (1988); 1992; 5(3):303-7. PubMed ID: 1740756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.